The first drug from Eli Lilly's new-look oncology group gets speedy review as Bilenker's team hones focus
The first drug from Eli Lilly’s Loxo buyout is nearing the finish line.
The pharma giant has received priority review for its RET inhibitor selpercatinib …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
